{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:22:38Z","timestamp":1790508158515,"version":"4.1.0"},"reference-count":31,"publisher":"VM Media Group sp. z o.o","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","oncology-and-radiotherapy.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reports of Practical Oncology &amp; Radiotherapy"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.rpor.2020.04.014","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T01:51:43Z","timestamp":1588902703000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer"],"prefix":"10.5603","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5725-3733","authenticated-orcid":false,"given":"O.","family":"Pons-Llanas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Collado-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Roldan-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-0924","authenticated-orcid":false,"given":"A.","family":"Conde-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Celada-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mart\u00ednez-Arcelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"P\u00e9rez-Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Carmona-Meseguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3501-0615","authenticated-orcid":false,"given":"J.","family":"Gimeno-Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Forner-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tormo-Mic\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Perez-Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"L\u00f3pez-Torrecilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3595","reference":[{"key":"10.1016\/j.rpor.2020.04.014_bib0005","series-title":"Chapter 27","article-title":"Prostate cancer: a comprehensive perspective","author":"Yales","year":"2013"},{"issue":"4","key":"10.1016\/j.rpor.2020.04.014_bib0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.29271\/jcpsp.2019.04.361","article-title":"Impact of prostate specific antigen level on oncological clinical outcomes after open radical prostatectomy","volume":"29","author":"Sungur","year":"2019","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.rpor.2020.04.014_bib0015","unstructured":"www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"issue":"1","key":"10.1016\/j.rpor.2020.04.014_bib0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0360-3016(99)00526-X","article-title":"Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation","volume":"47","author":"Stokes","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.rpor.2020.04.014_bib0025","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2018.06.103","article-title":"Patient reported outcomes of NRG Oncology\/RTOG 0232: A phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone in intermediate risk prostate Cancer","volume":"102","author":"Bruner","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.rpor.2020.04.014_bib0030","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ijrobp.2016.06.026","article-title":"Initial report of NRG Oncology\/RTOG 0232: A phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma","volume":"96","author":"Prestidge","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.rpor.2020.04.014_bib0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijrobp.2010.05.042","article-title":"Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience","volume":"81","author":"Sylvester","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.rpor.2020.04.014_bib0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2006.08.056","article-title":"Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation","volume":"67","author":"Zelefsky","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.rpor.2020.04.014_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.rpor.2020.04.014_bib0050","first-page":"315","article-title":"ESTRO\/EAU\/EORTC recommendations on permanent seed implantation for localized prostate cancer","volume":"57","author":"Ash","year":"2000","journal-title":"In: Radiother Oncol."},{"issue":"1","key":"10.1016\/j.rpor.2020.04.014_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2007.01.014","article-title":"Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO\/EAU\/EORTC recommendations on prostate brachytherapy","volume":"83","author":"Salembier","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.rpor.2020.04.014_bib0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus Conference","volume":"62","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phhys."},{"issue":"5","key":"10.1016\/j.rpor.2020.04.014_bib0065","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rpor.2020.04.014_bib0070","series-title":"National institutes of health, US department of health and human services. Common terminology criteria for adverse events (CTCAE), version 4.0. NIH publication 09-7473","author":"National Cancer Institute","year":"2010"},{"key":"10.1016\/j.rpor.2020.04.014_bib0075","unstructured":"The R Project for Statistical Computing. R version 3.2.3 (Wooden Christmas-tree)."},{"issue":"4","key":"10.1016\/j.rpor.2020.04.014_bib0080","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0360-3016(99)00499-X","article-title":"Palladium-103 brachytherapy for prostate carcinoma","volume":"46","author":"Blasko","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.rpor.2020.04.014_bib0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2006.08.056","article-title":"Multi-institutional analysis of long-term outcome for stages T1\u2013T2 prostate cancer treated with permanent seed implantation","volume":"67","author":"Zelefsky","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.rpor.2020.04.014_bib0090","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ijrobp.2010.01.005","article-title":"Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy","volume":"79","author":"Taira","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.rpor.2020.04.014_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.03.004","article-title":"Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center","volume":"32","author":"Marshall","year":"2014","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.rpor.2020.04.014_bib0100","doi-asserted-by":"crossref","first-page":"E213","DOI":"10.1016\/j.ijrobp.2015.07.1088","article-title":"Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate Cancer: Outcome in 966 patients","volume":"93","author":"Funk","year":"2015","journal-title":"Int J Radiat Oncol [Internet]. Elsevier"},{"issue":"4","key":"10.1016\/j.rpor.2020.04.014_bib0105","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ijrobp.2015.02.047","article-title":"Long-term efficacy and toxicity of low-dose-Rate 125I prostate brachytherapy as monotherapy in low-, intermediate-, and high-risk prostate Cancer","volume":"92","author":"Kittel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1065","key":"10.1016\/j.rpor.2020.04.014_bib0110","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150981","article-title":"Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: Practice and outcome analysis in a series of 2237 patients from 11 institutions","volume":"89","author":"Fellin","year":"2016","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1016\/j.rpor.2020.04.014_bib0115","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.rpor.2018.06.009","article-title":"Permanent seed implant brachytherapy in low-risk prostate cancer: Preoperative planning with 145 Gy versus real-time intraoperative planning with 160 Gy","volume":"23","author":"Pons-Llanas","year":"2018","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.rpor.2020.04.014_bib0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5858\/arpa.2011-0495-RA","article-title":"Implications of the international society of urological pathology modified gleason grading system","volume":"136","author":"Egevad","year":"2012","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.rpor.2020.04.014_bib0125","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ijrobp.2016.06.026","article-title":"Initial report of NRG Oncology\/RTOG 0232: A phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma","volume":"96","author":"Prestidge","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.rpor.2020.04.014_bib0130","doi-asserted-by":"crossref","first-page":"E795","DOI":"10.1016\/j.ijrobp.2011.11.040","article-title":"Long-term results of an RTOG phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate","volume":"82","author":"Lawton","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.rpor.2020.04.014_bib0135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ijrobp.2014.11.018","article-title":"Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: A propensity score matched analysis","volume":"91","author":"Smith","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rpor.2020.04.014_bib0140","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bju.14128","article-title":"Outcomes and toxicities in patients with intermediate\u2010risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy","volume":"121","author":"Schlussel Markovic","year":"2018","journal-title":"BJU Int"},{"issue":"Supl 1","key":"10.1016\/j.rpor.2020.04.014_bib0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.rpor.2020.04.014_bib0150","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2017.09.050","article-title":"Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate Cancer: Efficacy, toxicity, and quality of life outcomes","volume":"100","author":"Frank","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.rpor.2020.04.014_bib0155","doi-asserted-by":"crossref","first-page":"853","DOI":"10.7326\/0003-4819-158-12-201306180-00002","article-title":"Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis","volume":"158","author":"Hayes","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["Reports of Practical Oncology &amp; Radiotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1507136720300705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1507136720300705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T14:15:50Z","timestamp":1613657750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1507136720300705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1507136720300705"],"URL":"https:\/\/doi.org\/10.1016\/j.rpor.2020.04.014","relation":{},"ISSN":["1507-1367"],"issn-type":[{"value":"1507-1367","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Reports of Practical Oncology & Radiotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpor.2020.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}